» Articles » PMID: 32096603

Integrated Bioinformatics Analysis of the Crucial Candidate Genes and Pathways Associated with Glucocorticoid Resistance in Acute Lymphoblastic Leukemia

Overview
Journal Cancer Med
Specialty Oncology
Date 2020 Feb 26
PMID 32096603
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Glucocorticoids (GC) are the foundation of the chemotherapy regimen in acute lymphoblastic leukemia (ALL). However, resistance to GC is observed more frequently than resistance to other chemotherapy agents in patients with ALL relapse. Moreover, the mechanism underlying the development of GC resistance in ALL has not yet been fully uncovered. In this study, we used bioinformatic analysis methods to integrate the candidate genes and pathways participating in GC resistance in ALL and subsequently verified the bioinformatics findings with in vitro cell experiments. Ninety-nine significant common differentially expressed genes (DEGs) associated with GC resistance were determined by integrating two gene profile datasets, including GC-sensitive and -resistant samples. Using Kyoto Encyclopedia of Genes and Genomes (KEGG) and REACTOME pathways analysis, the signaling pathways in which DEGs were significantly enriched were clustered. The GC resistance-related biologically functional interactions were visualized as DEG-associated Protein-Protein Interaction (PPI) network complexes, with 98 nodes and 127 edges. MYC, a node which displayed the highest connectivity in all edges, was highlighted as the core gene in the PPI network. Increased C-MYC expression was observed in adriamycin-resistant BALL-1/ADR cells, which we demonstrated was also resistant to dexamethasone. These results outlined a panorama in which the solitary and scattered experimental results were integrated and expanded. The potential promising target of the candidate pathways and genes involved in GC resistance of ALL was concomitantly revealed.

Citing Articles

Regulation and Functions of α6-Integrin (CD49f) in Cancer Biology.

Khademi R, Malekzadeh H, Bahrami S, Saki N, Khademi R, Villa-Diaz L Cancers (Basel). 2023; 15(13).

PMID: 37444576 PMC: 10341356. DOI: 10.3390/cancers15133466.


A Predictive Disease Risk Model for Ankylosing Spondylitis: Based on Integrated Bioinformatic Analysis and Identification of Potential Biomarkers Most Related to Immunity.

Gao W, Hou R, Chen Y, Wang X, Liu G, Hu W Mediators Inflamm. 2023; 2023:3220235.

PMID: 37152368 PMC: 10159744. DOI: 10.1155/2023/3220235.


Identification of Hub Genes Associated with Resistance to Prednisolone in Acute Lymphoblastic Leukemia Based on Weighted Gene Co-expression Network Analysis.

Nekoeian S, Ferdowsian S, Asgari Y, Azizi Z Mol Biotechnol. 2023; 65(11):1913-1922.

PMID: 36877306 DOI: 10.1007/s12033-023-00707-0.


The regulatory role of PDE4B in the progression of inflammatory function study.

Su Y, Ding J, Yang F, He C, Xu Y, Zhu X Front Pharmacol. 2022; 13:982130.

PMID: 36278172 PMC: 9582262. DOI: 10.3389/fphar.2022.982130.


Population genetics of PDE4B (phosphodiesterase-4B) in neglected Native Americans: Implications for cancer pharmacogenetics.

Moreira R, Saraiva-Duarte J, Pereira A, Sosa-Macias M, Galaviz-Hernandez C, Santolalla M Clin Transl Sci. 2022; 15(6):1400-1405.

PMID: 35266293 PMC: 9199872. DOI: 10.1111/cts.13266.


References
1.
Maia S, Nicholas Haining W, Ansen S, Xia Z, Armstrong S, Seth N . Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia. Cancer Res. 2005; 65(21):10050-8. DOI: 10.1158/0008-5472.CAN-05-1574. View

2.
Haferlach T, Kohlmann A, Wieczorek L, Basso G, Te Kronnie G, Bene M . Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol. 2010; 28(15):2529-37. PMC: 5569671. DOI: 10.1200/JCO.2009.23.4732. View

3.
Hall C, Reynolds C, Kang M . Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235. Clin Cancer Res. 2015; 22(3):621-32. PMC: 4681691. DOI: 10.1158/1078-0432.CCR-15-0114. View

4.
Andersson A, Ma J, Wang J, Chen X, Gedman A, Dang J . The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet. 2015; 47(4):330-7. PMC: 4553269. DOI: 10.1038/ng.3230. View

5.
Carroll W, Raetz E . Clinical and laboratory biology of childhood acute lymphoblastic leukemia. J Pediatr. 2011; 160(1):10-8. DOI: 10.1016/j.jpeds.2011.08.006. View